公开(公告)号：US20210188831A1

公开(公告)日：2021-06-24

申请号：US17263333

申请日：2019-07-25

申请人： Chong Kun Dang Pharmaceutical Corp.

发明人： Chang Sik Lee ,  Jung Taek Oh ,  Hokeun Yun ,  Hyeseung Song ,  Hyunjin Michael Kim

IPC分类号： C07D413/14 ,  C07D413/04 ,  C07D417/14

摘要： The present invention relates to novel compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, optical isomers thereof or pharmaceutically acceptable salts thereof, a pharmaceutical use thereof, and a method for preparing the same. According to the present invention, the novel compounds, optical isomers thereof or pharmaceutically acceptable salts thereof have the histone deacetylase 6 (HDAC6) inhibitory activity, and are effective in preventing or treating HDAC6-related diseases, comprising infectious diseases; neoplasm; internal secretion; nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; eye and ocular adnexal diseases; circulatory diseases; respiratory diseases; digestive diseases; skin and subcutaneous tissue diseases; musculoskeletal system and connective tissue diseases; and teratosis or deformities, and chromosomal aberration.

公开(公告)号：US20230295142A1

公开(公告)日：2023-09-21

申请号：US18024081

申请日：2021-09-01

申请人： CHONG KUN DANG PHARMACEUTICAL CORP.

发明人： Chang Sik Lee ,  Jung Taek Oh ,  Hokeun Yun ,  Hyeseung Song ,  Hyunjin Michael Kim

IPC分类号： C07D413/14 ,  C07D413/10 ,  C07D487/10

CPC分类号： C07D413/14 ,  C07D413/10 ,  C07D487/10

摘要： The present invention relates to a novel compound having a selective HDAC6 inhibitory activity, stereoisomers thereof, pharmaceutically acceptable salts thereof, a use thereof in preparation of a therapeutic medicament, a pharmaceutical composition containing the same, a therapeutic method using the composition, and a method for preparing the same, wherein the novel compound having the selective HDAC6 inhibitory activity is represented by chemical formula (I) below.

公开(公告)号：US20230079386A1

公开(公告)日：2023-03-16

申请号：US17615363

申请日：2020-05-29

申请人： Chong Kun Dang Pharmaceutical Corp.

发明人： Chang Sik Lee ,  Jung Taek Oh ,  Hokeun Yun ,  Hyeseung Song ,  Hyunjin Michael Kim

IPC分类号： A61K31/4439 ,  A61K31/4245 ,  A61K31/437 ,  A61K31/4725 ,  A61K31/506 ,  A61K31/517 ,  A61K31/496 ,  A61K31/5377

摘要： The present invention relates to novel compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, a medicinal use thereof, and a method for preparing the same. The novel compounds according to the present invention, stereoisomers thereof or pharmaceutically acceptable salts thereof have the histone deacetylase 6 (HDAC6) inhibitory activity, and are effective in preventing or treating HDAC6-related diseases, comprising infectious diseases; neoplasm; endocrinopathy; nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; eye and ocular adnexal diseases; circulatory diseases; respiratory diseases; digestive diseases; skin and subcutaneous tissue diseases; musculoskeletal system and connective tissue diseases; and teratosis or deformities, or chromosomal aberration.

公开(公告)号：US11958844B2

公开(公告)日：2024-04-16

申请号：US17263333

申请日：2019-07-25

申请人： Chong Kun Dang Pharmaceutical Corp.

发明人： Chang Sik Lee ,  Jung Taek Oh ,  Hokeun Yun ,  Hyeseung Song ,  Hyunjin Michael Kim

IPC分类号： C07D413/14 ,  C07D413/04 ,  C07D417/14

CPC分类号： C07D413/14 ,  C07D413/04 ,  C07D417/14

摘要： The present invention relates to novel compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, optical isomers thereof or pharmaceutically acceptable salts thereof, a pharmaceutical use thereof, and a method for preparing the same. According to the present invention, the novel compounds, optical isomers thereof or pharmaceutically acceptable salts thereof have the histone deacetylase 6 (HDAC6) inhibitory activity, and are effective in preventing or treating HDAC6-related diseases, comprising infectious diseases; neoplasm; internal secretion; nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; eye and ocular adnexal diseases; circulatory diseases; respiratory diseases; digestive diseases; skin and subcutaneous tissue diseases; musculoskeletal system and connective tissue diseases; and teratosis or deformities, and chromosomal aberration.

公开(公告)号：US20230092890A1

公开(公告)日：2023-03-23

申请号：US17614967

申请日：2020-05-29

申请人： Chong Kun Dang Pharmaceutical Corp.

发明人： Chang Sik Lee ,  Jung Taek Oh ,  Hokeun Yun ,  Hyeseung Song ,  Hyunjin Michael Kim

IPC分类号： C07D413/14 ,  C07D417/14 ,  C07D491/107 ,  C07D471/04

摘要： The present invention relates to 1,3,4-oxadiazole derivative compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, a use thereof in preparation of a medicament, a pharmaceutical composition comprising the same, a therapeutic method using the composition, and a method for preparing the same, and the 1,3,4-oxadiazole derivative compounds are represented by a following chemical formula (I).